Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin’s lymphoma-Reference-Cited by-同舟云学术

Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin’s lymphoma

Published:2001-05 Issue:5 Volume:12 Page:661-667
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Borchmann P.,Schnell R.,Knippertz R.,Staak J.O.,Camboni G.M.,Bernareggi A.,Hübel K.,Staib P.,Schulz A.,Diehl V.,Engert A.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/12/5/661/19479253/12-5-661.pdf

Reference18 articles.

1. Risk-Benefit Assessment of Anthracycline Antibiotics in Antineoplastic Therapy;Abraham;Drug Safety,1996

2. Strategies for prevention of anthracycline cardiotoxicity;Basser;Cancer Treat Rev,1931

3. Current concepts Doxorubicin induced cardiomyopathie;Singal;N Engl J Med,1998

4. Characteristics of the binding of the anticancer agents mitoxantrone and ametantrone and related structures to deoxyribonucleic acids;Lown;Biochemistry,1985

5. Kinetics of the binding of mitoxantrone, ametantrone and analogues to DNA: Relationship with binding mode and antitumor activity;Denny;Anti-Cancer Drug Design,1990

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Encapsulation of pixantrone into PEGylated liposomes enhances its antineoplastic efficacy and reduces thymus toxicity;Journal of Drug Delivery Science and Technology;2023-09

2. A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trial;British Journal of Haematology;2022-04

3. Current Opinion on Pixantrone in the Treatment of Non-Hodgkin B-Cell Lymphoma;Therapeutics and Clinical Risk Management;2021-03

4. Efficacy and safety of pixantrone for the treatment of multiply relapsed or refractory aggressive non‐Hodgkin B‐cell lymphomas;European Journal of Haematology;2020-02-11

5. In vitro demonstration of synergism with pixantrone combined with targeted agents in lymphomas;British Journal of Haematology;2018-12-19